Evaluation of nanoparticle drug-delivery systems used in preclinical studies

Ther Deliv. 2021 Apr;12(4):325-336. doi: 10.4155/tde-2020-0116. Epub 2021 Mar 24.

Abstract

Multifunctional nanoparticles have been identified as a promising drug-delivery system for sustainable drug release. The structural and size tunability and disease-targeting ability of nanoparticles have made them more suitable for multiple drug loading and delivery, thereby enhancing therapeutic results through synergistic effects. Nanoparticulate carriers with specific features such as target specificity and stimuli-responsiveness enable selective drug delivery with lower potential side effects. In this review we have classified the recently published articles on polymeric and inorganic nanoparticle-mediated drug delivery into three different categories based on functionality and discussed their efficiency for drug delivery and their therapeutic outcomes in preclinical models. Most of the drug-loaded nanodelivery systems discussed have demonstrated negligible or very low systemic toxicity throughout the experimental period in animal models compared with free drug administration. In addition, some challenges associated with the translation of nanoparticle-based drug carrier responses to clinical application are highlighted.

Keywords: EPR tumor targeting; active tumor targeting; biodistribution; dual drug delivery; in vivo performance; inorganic nanoparticles; polymeric nanoparticles; single drug delivery; stimuli-responsive drug release; synergistic activity; targeted ligand/receptor.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Carriers
  • Drug Delivery Systems*
  • Nanoparticles*
  • Polymers

Substances

  • Drug Carriers
  • Polymers